Cocrystal Pharma Inc (COCP) is not a strong buy for a beginner investor with a long-term strategy at this time. Despite some bullish technical indicators, the lack of positive financial performance, absence of news catalysts, and no significant trading trends make it a cautious hold rather than a buy.
The technical indicators show a mixed picture. The MACD is positive and expanding, suggesting bullish momentum. The RSI is neutral at 69.976, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock has shown volatility, with a 4.67% regular market gain but a -3.19% pre-market and -2.89% post-market decline. Support and resistance levels indicate potential price fluctuations, with key support at 1.226 and resistance at 1.883.
Bullish moving averages and positive MACD expansion.
No recent news, weak financial performance with declining EPS (-43.75% YoY) and net income (-25.72% YoY), and no significant trading trends from hedge funds or insiders.
In Q4 2025, revenue remained at 0 with no growth YoY. Net income dropped to -2,426,000 (-25.72% YoY), and EPS fell to -0.18 (-43.75% YoY). Gross margin remained at 0 with no growth.
No analyst rating or price target changes available.